<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Immunsuppressive therapy is a major therapy for severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, and antithymocyte /antilymphocyte globulin (ATG/ALG) is usually used </plain></SENT>
<SENT sid="1" pm="."><plain>This study investigated the therapeutic effect of ATG/ALG on severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and explored the management of therapy-related complications </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Clinical data of 28 children with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> who received ATG/ALG treatment from December, 1994 through to September, 2005 were analyzed retrospectively </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Of the 28 patients, 2 were nearly cured (7.1%), 4 were relieved (14.3%) and 12 were improved (42.9%) based on a <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>/white blood cell/platelet count </plain></SENT>
<SENT sid="4" pm="."><plain>These results represented an overall effective rate of 64.3% </plain></SENT>
<SENT sid="5" pm="."><plain>Clinical evidence of <z:e sem="disease" ids="C0036830" disease_type="Disease or Syndrome" abbrv="">serum sickness</z:e> developed in 19 patients, manifesting as <z:hpo ids='HP_0001945'>fever</z:hpo> (n = 9), <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">cutaneous eruptions</z:e> (n = 12), <z:hpo ids='HP_0002829'>arthralgias</z:hpo> (n = 7), <z:hpo ids='HP_0003326'>myalgia</z:hpo> (n = 7) and arthrocele (n = 3) </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0036830" disease_type="Disease or Syndrome" abbrv="">Serum sickness</z:e> occurred 5-17 days after ATG/ALG administration and lasted for 1-15 days (mean 4.4 days) </plain></SENT>
<SENT sid="7" pm="."><plain>Three children with mild <z:e sem="disease" ids="C0036830" disease_type="Disease or Syndrome" abbrv="">serum sickness</z:e> symptoms recovered without any treatment </plain></SENT>
<SENT sid="8" pm="."><plain>The symptoms of the other 16 patients disappeared after 3-5 days of <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> treatment (10 mg/kg daily) </plain></SENT>
<SENT sid="9" pm="."><plain>However, 3 patients had relapses at 2-4 days after termination of <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> therapy </plain></SENT>
<SENT sid="10" pm="."><plain>Another course of <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> therapy was administered to the 3 patients until the symptoms disappeared </plain></SENT>
<SENT sid="11" pm="."><plain>The patients with no <z:e sem="disease" ids="C0036830" disease_type="Disease or Syndrome" abbrv="">serum sickness</z:e> or with mild <z:e sem="disease" ids="C0036830" disease_type="Disease or Syndrome" abbrv="">serum sickness</z:e> had a better response to ATG/ALG therapy than those who had severe <z:e sem="disease" ids="C0036830" disease_type="Disease or Syndrome" abbrv="">serum sickness</z:e> (100% vs 60%; P &lt; 0.05) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: ATG/ALG therapy for severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> is effective </plain></SENT>
<SENT sid="13" pm="."><plain><z:e sem="disease" ids="C0036830" disease_type="Disease or Syndrome" abbrv="">Serum sickness</z:e> is a common complication in children with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> following ATG/ALG therapy, but can be improved by <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> application </plain></SENT>
</text></document>